HTG Molecular Diagnostics, which markets a diagnostic platform for complex molecular profiling, filed on Tuesday with the SEC to raise up to $60 million in an initial public offering. The Tucson, AZ-based company, which was founded in 1997 and booked $3 million in sales for the 12 months ended September 30, 2014, plans to list on the NASDAQ under the symbol HTGM. HTG Molecular Diagnostics initially filed confidentially on September 23, 2014. Canaccord Genuity, Leerink Partners and JMP Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
